GoodRx Holdings

Government Pricing Reforms And Tech Rivalries Will Reduce Future Prospects

AnalystLowTarget

Not Invested

Consensus Narrative from 14 Analysts

Published

26 Aug 25

Updated

26 Aug 25

AnalystLowTarget's Fair Value

US$3.40

27.9% overvalued

26 Aug

US$4.35

-44.9%

2.4%

-44.9%

2.4%

Author's Valuation

US$3.4

27.9% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$3.4

27.9% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.78%

Healthtech revenue growth rate

4.56%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.73%

Calculation

US$91.01m

Earnings '28

13.40x

PE Ratio '28

US$1.22b

Market Cap '28

US$1.22b

Market Cap '28

279.47m

No. shares '28

US$4.36

Share Price '28

US$4.36 Share Price '28

Discounted to 2025 @ 8.73% p.a.

US$3.39

Fair Value '25